Talks (61)
Luspatercept in Low risk MDS
Jun 14
Engraftment dates
Mar 07
breast cancer
Mar 01
CAR-T
Feb 23
hemophilia A
Feb 06
ALL
Feb 03
BCMA
Feb 03
ischemic stroke
Jan 27
radiation therapy
Jan 26
Hemophilia
Jan 13
AML
Jan 06
EHA 2022 Congress
May 19
Daratumumab
May 19
Treatment Expansion
Apr 22
Mortality Predictors
Apr 22
Induction Therapy
Apr 18
Dr. Krackhard
Apr 18
Dr. Tricot
Apr 06
Patient Needs
Apr 06
Risk Stratification
Mar 25
Dr. Richardson
Mar 25
Future Prospects
Mar 21
Dr. Costa
Mar 21
MM
Mar 18
ASTCT
Mar 18
Autophagy
Mar 14
AJMC
Mar 14
Cevostamab
Mar 11
FDA Fast Track
Mar 11
Improving MM
Mar 09
Bispecific Antibody
Mar 09
PET/CT Utility
Mar 07
Biospecific Antibody
Mar 07
Anti-CD38 Antibody
Mar 07
Proactive Care
Mar 02
Biomarkers
Mar 02
Genomic Testing
Nov 05
MRD in AML
Nov 05
MM + Covid
Nov 04
Improved ORR in AML
Nov 03
haplo-SCT in AML
Nov 03
NK Cellular Therapy
Nov 03
Metabolism-based
Nov 01
MM: Trials 🚀
Oct 29
Maintenance Therapy
Oct 29
Radiotherapy
Oct 29
Imatinib in CML
Oct 28
TRANSCEND CLL 004
Oct 28
Genistein in AML
Oct 27
New Treatment AML
Oct 27
Maintenance Therapy
Oct 26
Insensitive to Chemo
Oct 26
Intellia Therapeutic
Oct 25
Medication Adoption
Oct 25
MM: Targeting RRM2
Oct 22
Advances in AML
Oct 22
CPX-351 in AML
Oct 22
Dr. Wierda on CLL
Oct 22
Phase 2 KarMMa trial
Oct 15
CRISPR therapy
Oct 15